March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
The Potential of Nanolipossomes-Encapsulated Bevacizumab (Avalong) in Prolong VEGF-Inhibition and Enhancing Choroidal Neovascularization -Targeting Following Intravitreal Injection
Author Affiliations & Notes
  • Jose A. Cardillo
    Retina Department, Hospital de Olhos de Araraquara, Araraquara, SP, Brazil
    Retina Department,
    Federal University of São Paulo, São Paulo, SP, Brazil
  • Alessandro J. Dare
    Retina Department, Hospital de Olhos de Araraquara, Araraquara, SP, Brazil
    Retina Department, Centro Brasileiro de Especialidades Oftalmológicas, CBEO, Araraquara, SP, Brazil
  • Acacio A. Lima Filho
    Federal University of São Paulo, São Paulo, SP, Brazil
  • Anselmo G. Oliveira
    Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil
  • Rubens Belfort, Jr.
    Retina Department,
    Federal University of São Paulo, São Paulo, SP, Brazil
  • Footnotes
    Commercial Relationships  Jose A. Cardillo, None; Alessandro J. Dare, None; Acacio A. Lima Filho, None; Anselmo G. Oliveira, None; Rubens Belfort, Jr., None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4637. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jose A. Cardillo, Alessandro J. Dare, Acacio A. Lima Filho, Anselmo G. Oliveira, Rubens Belfort, Jr.; The Potential of Nanolipossomes-Encapsulated Bevacizumab (Avalong) in Prolong VEGF-Inhibition and Enhancing Choroidal Neovascularization -Targeting Following Intravitreal Injection. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4637.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the potential of new and optimized bevacizumab-liposomal formulation to improve drug availability, bioactivity and vessels targeting after intravitreal administration.

Methods: : Bevacizumab was encapsulated into liposomes via the dehydration-rehydration method tested in an animal model. Left eyes of rabbits received liposomal bevacizumab and the right eyes were injected with the conventional soluble formulation. The free drug concentration in aqueous humor and vitreous samples at Days 3, 7, 14, and 29 after the injection was determined by enzyme-linked immune sorbent assay. The comparative inhibitory efficiency of bevacizumab in both conventional and liposomal formulation was determined by analyzing the gene expression of VEGF in human fibroblast cell line. Electronic microscopy (EM) of the retina and electro retinography (ERG) was performed to rule out and potential side effect.

Results: : Mean concentration of free bevacizumab in the eyes receiving liposomal bevacizumab compared with the eyes injected with soluble bevacizumab was 7 (24.5 versus 3.5 microg/mL) times higher at Days 29. Mean concentration of free bevacizumab in the aqueous humor of both injected eyes was almost the same at the different intervals. The In vitro inhibitory efficiency of the liposomal-bezacizumab formulation was 6 times greater than the soluble Bevacizumab, possible to its higher cell targeting and affinity. No significant EM or ERG findings were observed.

Conclusions: : Optimized pharmacokinetics and physicochemical properties obtained with Bevacizumab in a liposomal formulation, potentially enhancing the intravitreal half-life and its ability to interact with endothelial cells are important factors to consider for the treatment of Choroidal Neovascularization and other angiogenesis-dependent diseases of the eye.

Keywords: retina • age-related macular degeneration • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×